According to Novartis, Kesimpta is the first targeted B cell ... The AI effect in pharma commercial strategy: From data to re... Discover how AI is transforming the pharma commercial strategy.

Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well ...

Multiple sclerosis drug Kesimpta sales reached $838 million, up +28%, reflecting increased demand for a high-efficacy product with convenient self-administered dosing. Guidance: Novartis also ...

As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ramped up legal actions against its competitors. | As Novartis builds an empire of radiopharmaceuticals, the Swiss pharma has ...

Novartis is scheduled to report results for ... neuroscience medicine Kesimpta and cardiovascular drug Entresto--the patent of which expires in 2025--are expected to be the key drivers in the ...

Novartis raised its 2024 earnings guidance for the third time on Tuesday, buoyed by wider use of its prescription drugs, but ...

Novartis said on Tuesday it was doing early research on next-generation obesity drugs that could be more tolerable or given ...

Kesimpta, Kisqali, Cosentyx, Pluvicto and Leqvio. The top line beat the Zacks Consensus Estimate of $12.6 billion. Shares of Novartis have risen 14.6% year to date compared with the industry’s ...

On Tuesday, Novartis AG (NYSE:NVS) reported third-quarter sales of $12.823 billion, up 9% (+10% on constant currency), beating the consensus of $12.76 billion. Volume contributed 12 percentage ...